Fredun Pharmaceuticals LtdQ2 FY25Pharmaceuticals & Biotechnology

Fredun Pharmaceuticals Ltd

Q2 FY25 Earnings Call Analysis

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

Yes

Order

Yes

Capex

Yes

4 of 5 growth signals are positive — a strong management growth story.

Revenue guidance

Category 3

→Targeting 15% to 20% year-on-year revenue growth overall.
→Ambition to double revenue and PAT within 3 to 4 years, aiming for INR 800+ crore top line and INR 90+ crore PAT.
→Vintage business expected to grow around 15% to 18% annually, supported by 1,290 product registrations in the pipeline.
→New age business, including Fredun Gx and pet care, targeted to reach INR 150 crore in next years with higher gross margins (above 50%).
→Plan to eliminate low-margin products and improve cost efficiencies with expanded manufacturing capacity.
→Anticipate growth from new age segments such as pet care, nutrition, and wellness.
→Working capital improvements expected to stabilize cash flows and support growth sustainably.
→Strong order book with confirmed orders covering a 6-month period supports steady growth visibility.

Category 1

→Targeting 15% to 20% year-on-year revenue growth going forward.
→Aim to double revenue and PAT in the next 3 to 4 years, targeting INR 800+ crore top line and INR 90+ crore PAT.
→EBITDA margins expected to improve as new age business (with above 50% gross margins) scales up.
→New age business segments (pet care, nutrition, mobility, wellness) expected to grow at 35% to 40% CAGR.
→Shift towards branded products and higher margin offerings to enhance profitability.
→Expect cost efficiencies and continuous improvement to drive improved margins and profitability.
→Debtors and inventory days expected to stabilize, supporting better cash flows and earnings visibility.
→No bad debts historically; confident of sustaining profitable growth and cash flow improvements.

Get access to all 5 sections — revenue, margin, fundraise, orderbook, and capex — for Fredun Pharmaceuticals Ltd and 1,400+ other companies.

Yes

→The company is definitely planning a fundraise and will evaluate requirements soon.
→No fixed timeline mentioned, but fundraising is expected in the coming months.
→Currently, there is no long-term debt; most debt is working capital.
→Even without raising funds in the next 1 to 6 months, growth is not expected to be hampered.
→The company has successfully grown about 30% last financial year without raising funds.
→Debt-equity ratio is around 1:1; the company is comfortable but open to equity infusion to support high growth plans.

Yes

→Fredun Pharmaceuticals has a firm order book valued at around INR 200 crores.
→These orders cover both export and local markets.
→Orders from export markets are confirmed for a 6-month period.
→Local market orders, including third-party orders, also generally cover a 6-month period.
→The company does not record orders in its system unless they are confirmed.
→This implies an assured order book of approximately two quarters for the vintage business and associated segments.

Yes

→Diagnostic center expansion: Planning to open a new diagnostic center in north Mumbai by end of the year; aiming to expand to multiple large cities over next 18 months.
→Per center capex for diagnostic centers estimated around INR 6-8 crores.
→Expansion of manufacturing capacity: Targeting to have one of the largest single-location plants in India within next 18-24 months to support new age business growth.
→Continuous investment in creating efficiencies and manufacturing capabilities to support growth and margin expansion.
→Strategic acquisition: Acquired One Pet Stop to access 4,000 pet customers and expand pet care ecosystem.
→Future fundraising planned to support growth and capital requirements; no immediate pressure on funds due to current working capital debt structure.

How does Fredun Pharmaceuticals Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Fredun Pharmaceuticals Ltd

Rev 3Mar 1

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Fredun Pharmaceuticals Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.